Lysosomal Storage Disorders

Abstract

Lysosomes are intracellular organelles that are responsible for degrading and recycling macromolecules. Lysosomal diseases (LDs) are a group of rare inherited diseases caused by deleterious variants affecting genes that encode the lysosomal enzymes, their transporter or their cofactor. Among LDs that are associated with lung involvement and/or interstitial lung disease (ILD) acid sphingomyelinase deficiency [ASMD formerly called Niemann–Pick A, AB, and B diseases]) is the most common. An history of lower respiratory tract infections and exertional dyspnea are the most frequent respiratory manifestations. In ASMD, ILD is frequent and is usually associated with spleen and/or liver enlargement, low platelet count, and low level of high-density lipoprotein cholesterol. A restrictive lung functional pattern and a reduction in DLCO value are usually observed. Analysis of bronchoalveolar lavage fluid and lung biopsy showing foamy cells can orientate the diagnosis, based on the demonstration of an enzymatic deficiency in sphingomyelinase in the blood, associated with biallelic pathogenic variants of the SMPD1 gene. An enzyme replacement therapy (ERT), based on intravenous recombinant enzyme infusions (olipudase alfa), is available from 2021 with very encouraging results both in pediatric and adult patients affected with type B or AB. Olipudase alfa administration decreased liver and spleen volume, increased DLCO value and improved radiological lung involvement. Available enzyme replacement therapy supports an early diagnosis to implement therapy before any irreversible organ damage.

Keywords

ASMD - splenomegaly - thrombocytopenia

Publication History

Received: 01 July 2025

Accepted: 02 October 2025

Accepted Manuscript online:
03 October 2025

Article published online:
29 October 2025

• References

• 1 Ginzburg L, Kacher Y, Futerman AH. The pathogenesis of glycosphingolipid storage disorders. Semin Cell Dev Biol 2004; 15 (04) 417-431
• 2 Pu J, Guardia CM, Keren-Kaplan T, Bonifacino JS. Mechanisms and functions of lysosome positioning. J Cell Sci 2016; 129 (23) 4329-4339
• 3 Parenti G, Medina DL, Ballabio A. The rapidly evolving view of lysosomal storage diseases. EMBO Mol Med 2021; 13 (02) e12836
• 4 Peters H, Ellaway C, Nicholls K, Reardon K, Szer J. Treatable lysosomal storage diseases in the advent of disease-specific therapy. Intern Med J 2020; 50 (Suppl. 04) 5-27
• 5 Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281 (03) 249-254
• 6 Borie R, Berteloot L, Kannengiesser C. et al. Rare genetic interstitial lung diseases: a pictorial essay. Eur Respir Rev 2024; 33 (174) 240101
• 7 Bowman SL, Bi-Karchin J, Le L, Marks MS. The road to lysosome-related organelles: Insights from Hermansky-Pudlak syndrome and other rare diseases. Traffic 2019; 20 (06) 404-435
• 8 Faverio P, Stainer A, De Giacomi F. et al. Molecular pathways and respiratory involvement in lysosomal storage diseases. Int J Mol Sci 2019; 20 (02) 327
• 9 Confalonieri M, Vitacca M, Scala R. et al; AIPO Pneumoloped Group. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study. Orphanet J Rare Dis 2019; 14 (01) 62
• 10 Sheth J, Joseph JJ, Shah K, Muranjan M, Mistri M, Sheth F. Pulmonary manifestations in Niemann-Pick type C disease with mutations in NPC2 gene: case report and review of literature. BMC Med Genet 2017; 18 (01) 5
• 11 von Ranke FM, Pereira Freitas HM, Mançano AD. et al. Pulmonary Involvement in Niemann-Pick disease: a state-of-the-art review. Lung 2016; 194 (04) 511-518
• 12 Vanier MT, Ferlinz K, Rousson R. et al. Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa. Hum Genet 1993; 92 (04) 325-330
• 13 Froissart R, Pettazzoni M, Pagan C, Levade T, Vanier MT. Acid sphingomyelinase deficiency: laboratory diagnosis, genetic and epidemiologic aspects of a 50-year French cohort. Mol Genet Metab 2025; 145 (01) 109081
• 14 Thurberg BL, Wasserstein MP, Schiano T. et al. Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann-Pick disease type B). Am J Surg Pathol 2012; 36 (08) 1234-1246
• 15 McGovern MM, Avetisyan R, Sanson BJ, Lidove O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis 2017; 12 (01) 41
• 16 Wasserstein M, Dionisi-Vici C, Giugliani R. et al. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD). Mol Genet Metab 2019; 126 (02) 98-105
• 17 Geberhiwot T, Wasserstein M, Wanninayake S. et al. Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A/B). Orphanet J Rare Dis 2023; 18 (01) 85
• 18 Tirelli C, Rondinone O, Italia M. et al. The genetic basis, lung involvement, and therapeutic options in Niemann-Pick disease: a comprehensive review. Biomolecules 2024; 14 (02) 211
• 19 McGovern MM, Dionisi-Vici C, Giugliani R. et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. Genet Med 2017; 19 (09) 967-974
• 20 Wasserstein MP, Desnick RJ, Schuchman EH. et al. The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics 2004; 114 (06) e672-e677
• 21 Wasserstein MP, Schuchman EH, Adam MP, Feldman J, Mirzaa GM. Acid sphingomyelinase deficiency. In Adam MP. et al, eds: GeneReviews. University of Washington; Seattle, WA: 2006
• 22 Pavlů-Pereira H, Asfaw B, Poupctová H. et al. Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study. J Inherit Metab Dis 2005; 28 (02) 203-227
• 23 Simonaro CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH. The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet 2002; 71 (06) 1413-1419
• 24 McGovern MM, Wasserstein MP, Giugliani R. et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics 2008; 122 (02) e341-e349
• 25 McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann-Pick disease. Genet Med 2013; 15 (08) 618-623
• 26 Cassiman D, Packman S, Bembi B. et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): literature review and report of new cases. Mol Genet Metab 2016; 118 (03) 206-213
• 27 Wasserstein MP, Aron A, Brodie SE, Simonaro C, Desnick RJ, McGovern MM. Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J Pediatr 2006; 149 (04) 554-559
• 28 McGovern MM, Wasserstein MP, Aron A, Desnick RJ, Schuchman EH, Brodie SE. Ocular manifestations of Niemann-Pick disease type B. Ophthalmology 2004; 111 (07) 1424-1427
• 29 Wasserstein MP, Larkin AE, Glass RB, Schuchman EH, Desnick RJ, McGovern MM. Growth restriction in children with type B Niemann-Pick disease. J Pediatr 2003; 142 (04) 424-428
• 30 Wasserstein M, Godbold J, McGovern MM. Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B. J Inherit Metab Dis 2013; 36 (01) 123-127
• 31 Eskes ECB, van Dussen L, Aerts JMFG. et al. Acid sphingomyelinase deficiency and Gaucher disease in adults: similarities and differences in two macrophage storage disorders. JIMD Rep 2024; 65 (05) 330-340
• 32 Volders P, Van Hove J, Lories RJ. et al. Niemann-Pick disease type B: an unusual clinical presentation with multiple vertebral fractures. Am J Med Genet 2002; 109 (01) 42-51
• 33 Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis 2007; 30 (05) 654-663
• 34 McGovern MM, Wasserstein MP, Bembi B. et al. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation. Orphanet J Rare Dis 2021; 16 (01) 212
• 35 Mendelson DS, Wasserstein MP, Desnick RJ. et al. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology 2006; 238 (01) 339-345
• 36 Borie R, Crestani B, Guyard A, Lidove O. Interstitial lung disease in lysosomal storage disorders. Eur Respir Rev 2021; 30 (160) 200363
• 37 Guillemot N, Troadec C, de Villemeur TB, Clément A, Fauroux B. Lung disease in Niemann-Pick disease. Pediatr Pulmonol 2007; 42 (12) 1207-1214
• 38 Capron T, Trigui Y, Gautier C, Puech B, Chanez P, Reynaud-Gaubert M. Respiratory impairment in Niemann-Pick B disease: two case reports and review for the pulmonologist. Respir Med Res 2019; 76: 13-18
• 39 Cappellini MD, Motta I, Barbato A. et al. Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: an algorithm to support the diagnosis. Eur J Intern Med 2023; 108: 81-84
• 40 Hollak CEM, de Sonnaville ES, Cassiman D. et al. Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients. Mol Genet Metab 2012; 107 (03) 526-533
• 41 Mauhin W, Levade T, Vanier MT, Froissart R, Lidove O. Prevalence of cancer in acid sphingomyelinase deficiency. J Clin Med 2021 10 21 •••
• 42 Freitas HMP. et al. Doença de Niemann-pick tipo B: Avaliação do comprometimento pulmonar por TCAR. J Bras Pneumol 2017; 43: 451-455
• 43 Hervé A, Marchand-Adam S, Fabre A. et al. Maladie de Niemann-Pick de type B révélée par une atteinte bronchopulmonaire. Rev Mal Respir 2008; 25 (07) 861-866
• 44 Nicholson AG, Florio R, Hansell DM. et al. Pulmonary involvement by Niemann-Pick disease. A report of six cases. Histopathology 2006; 48 (05) 596-603
• 45 Mauhin W, Guffon N, Vanier MT. et al; ASSUR Study Group. Acid sphingomyelinase deficiency in France: a retrospective survival study. Orphanet J Rare Dis 2024; 19 (01) 289
• 46 Mengel E, Muschol N, Weinhold N. et al. A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in Germany. Orphanet J Rare Dis 2024; 19 (01) 161
• 47 Pulikottil-Jacob R, Dehipawala S, Smith B. et al. Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: a retrospective chart review study. Mol Genet Metab Rep 2023; 38: 101040
• 48 Doerr A, Farooq M, Faulkner C. et al. Diagnostic odyssey for patients with acid sphingomyelinase deficiency (ASMD): exploring the potential indicators of diagnosis using quantitative and qualitative data. Mol Genet Metab Rep 2024; 38: 101052
• 49 Scarpa M, Barbato A, Bisconti A. et al. Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy-a Delphi consensus. Intern Emerg Med 2023; 18 (03) 831-842
• 50 Breilyn MS, Zhang W, Yu C, Wasserstein MP. Plasma lyso-sphingomyelin levels are positively associated with clinical severity in acid sphingomyelinase deficiency. Mol Genet Metab Rep 2021; 28: 100780
• 51 Wasserstein M, Lachmann R, Hollak C. et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: one-year results. Genet Med 2022; 24 (07) 1425-1436
• 52 Giese AK, Mascher H, Grittner U. et al. A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease. Orphanet J Rare Dis 2015; 10: 78
• 53 Ries M, Schaefer E, Lührs T. et al. Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C. J Inherit Metab Dis 2006; 29 (05) 647-652
• 54 Lidove O, Le Fèvre L, Goasguen N. et al. [Acid sphingomyelinase deficiency and spleen trauma: splenectomy or not splenectomy?]. Rev Med Interne 2015; 36 (09) 619-622
• 55 Nicholson AG, Wells AU, Hooper J, Hansell DM, Kelleher A, Morgan C. Successful treatment of endogenous lipoid pneumonia due to Niemann-Pick type B disease with whole-lung lavage. Am J Respir Crit Care Med 2002; 165 (01) 128-131
• 56 Griese M, Brasch F, Aldana VR. et al. Respiratory disease in Niemann-Pick type C2 is caused by pulmonary alveolar proteinosis. Clin Genet 2010; 77 (02) 119-130
• 57 Uyan ZS, Karadağ B, Ersu R. et al. Early pulmonary involvement in Niemann-Pick type B disease: lung lavage is not useful. Pediatr Pulmonol 2005; 40 (02) 169-172
• 58 Mannem H, Kilbourne S, Weder M. Lung transplantation in a patient with Niemann-Pick disease. J Heart Lung Transplant 2019; 38 (01) 100-101
• 59 O'Neill RS, Belousova N, Malouf MA. Pulmonary Type B Niemann-Pick disease successfully treated with lung transplantation. Case Rep Transplant 2019; 2019: 9431751
• 60 Ding F, Mehta AC, Arrossi AV. Successful lung transplantation in a patient with Niemann-Pick disease. J Heart Lung Transplant 2019; 38 (05) 582-583
• 61 Mora VMC, Osorio JSC, Iturbe DF. et al. Double-lung transplantation in a patient with pulmonary type B Niemann-Pick disease: a valid treatment option. Case Rep Transplant 2022; 2022: 5428381
• 62 Tirelli C, Arbustini E, Meloni F. Bilateral cystic bronchiectasis as novel phenotype of Niemann-Pick disease type B successfully treated with double lung transplantation. Chest 2021; 159 (05) e293-e297
• 63 McGovern MM, Wasserstein MP, Kirmse B. et al. Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency). Genet Med 2016; 18 (01) 34-40
• 64 Wasserstein MP, Jones SA, Soran H. et al. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency. Mol Genet Metab 2015; 116 (1-2): 88-97
• 65 Diaz GA, Jones SA, Scarpa M. et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. Genet Med 2021; 23 (08) 1543-1550
• 66 Wasserstein MP, Lachmann R, Hollak C. et al. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial. Orphanet J Rare Dis 2023; 18 (01) 378